Ciaran Cooper - Mediantechn Clinical Devel
| ALMDT Stock | EUR 3.77 0.13 3.57% |
Insider
Ciaran Cooper is Clinical Devel of Mediantechn
| Phone | 33 4 93 33 37 77 |
| Web | https://www.mediantechnologies.com |
Mediantechn Management Efficiency
The company has return on total asset (ROA) of (0.2475) % which means that it has lost $0.2475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.1128) %, meaning that it generated substantial loss on money invested by shareholders. Mediantechn's management efficiency ratios could be used to measure how well Mediantechn manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Louis Tannyeres | Kalray SA | 65 | |
| Herve MBA | Eurobio Scientific SA | 64 | |
| Linda MSc | OSE Pharma SA | 56 | |
| Benot Dinechin | Kalray SA | N/A | |
| JeanPascal PharmD | OSE Pharma SA | N/A | |
| Jacques Martin | Eurobio Scientific SA | N/A | |
| Dominique MD | OSE Pharma SA | 68 | |
| Alain MD | OSE Pharma SA | N/A | |
| JeanMichel Grandmougin | Eurobio Scientific SA | 62 | |
| Silvia MD | OSE Pharma SA | N/A | |
| Denis Fortier | Eurobio Scientific SA | 55 | |
| Erwan Menard | Kalray SA | N/A | |
| Brangre Vasseur | OSE Pharma SA | N/A | |
| Thomas Iff | Eurobio Scientific SA | N/A | |
| Thomas Lamy | Biosynex | N/A | |
Management Performance
| Return On Equity | -5.11 | |||
| Return On Asset | -0.25 |
Mediantechn Leadership Team
Elected by the shareholders, the Mediantechn's board of directors comprises two types of representatives: Mediantechn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mediantechn. The board's role is to monitor Mediantechn's management team and ensure that shareholders' interests are well served. Mediantechn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mediantechn's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fredrik Brag, Co-Founder, Chairman, CEO and Pres | ||
| MD MS, Chief Officer | ||
| JeanChristophe Montigny, Chief Officer | ||
| Takashi Hayashi, Managing Japan | ||
| Bill Broderick, VP Services | ||
| Ciaran Cooper, Clinical Devel | ||
| Nicolas Dano, Chief Unit | ||
| Sophie Campagno, Chief Services | ||
| Marjorie Kooman, VP Relations | ||
| Emmanuelle Leygues, Head Communications |
Mediantechn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mediantechn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.11 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (0.80) % | |||
| Operating Margin | (0.77) % | |||
| Current Valuation | 117.65 M | |||
| Shares Outstanding | 15.74 M | |||
| Shares Owned By Insiders | 28.90 % | |||
| Shares Owned By Institutions | 18.72 % | |||
| Price To Earning | (13.07) X | |||
| Price To Book | 271.96 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mediantechn Stock Analysis
When running Mediantechn's price analysis, check to measure Mediantechn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediantechn is operating at the current time. Most of Mediantechn's value examination focuses on studying past and present price action to predict the probability of Mediantechn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediantechn's price. Additionally, you may evaluate how the addition of Mediantechn to your portfolios can decrease your overall portfolio volatility.